62 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
10 Aug 23
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
4:10pm
; the impact of the COVID-19 pandemic on Athira’s business, research and
clinical development plans and timelines, and the regulatory process … clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product
8-K
EX-99.1
zl54ql9yn1o7bs2z
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-99.1
x7mtnhxtjx
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
b10biqh
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
EX-99.2
zj6kmm v6sf6z9gdwbz
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
gacqjiemo307g2p
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
6la4 znwx9qsl
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.2
033p2to
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.1
rq3sdjz
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
9prfpmk1
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
nz6mae
16 May 22
Additional proxy soliciting materials
6:32pm
8-K
EX-99.1
44gvd qck
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm